Immatics (IMTX) Operating Margin (2019 - 2025)
Immatics recorded quarterly Operating Margin of 196.76% in Q4 2025, up 81.32% quarter-over-quarter from 1053.27% in Q3 2025, and down 19948.0% year-over-year from N/an in Q4 2024.
Immatics' Operating Margin history runs 7 years deep, the most recent figure standing at 196.76% for Q4 2025.
- In Q4 2025, Operating Margin fell 19948.0% year-over-year to 196.76%; the TTM figure through Dec 2025 stood at 382.54% (down 34514.0% YoY), while the FY2025 annual figure was 377.11%, down 35233.0% from the prior year.
- Operating Margin came in at 196.76% for Q4 2025 at Immatics, up from 1053.27% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 66.56% in Q1 2022 to a low of 1121.53% in Q2 2025.
- A 5-year average of 260.99% and a median of 159.83% in 2022 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin soared 56382 bps in 2024 and sank 105572 bps in 2025, its largest moves.
- Immatics' Operating Margin stood at 102.12% in 2021, then surged by 100 bps to 0.12% in 2022, then slumped by 145732 bps to 174.07% in 2023, then surged by 102 bps to 2.73% in 2024, then slumped by 7312 bps to 196.76% in 2025.
- According to Business Quant data, Operating Margin over the past three periods registered 196.76%, 1053.27%, and 1121.53% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -196.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -196.76% |
| Sep 30, 2025 | -1,053.27% |
| Jun 30, 2025 | -1,121.53% |
| Mar 31, 2025 | -190.37% |
| Dec 31, 2024 | 2.73% |
| Sep 30, 2024 | 2.45% |
| Jun 30, 2024 | -141.64% |
| Mar 31, 2024 | -44.50% |
| Dec 31, 2023 | -174.07% |
| Sep 30, 2023 | -561.37% |
| Jun 30, 2023 | -64.04% |
| Mar 31, 2023 | -269.80% |
| Dec 31, 2022 | 0.12% |
| Sep 30, 2022 | -145.58% |
| Jun 30, 2022 | -96.76% |
| Mar 31, 2022 | 66.56% |
| Dec 31, 2021 | -102.12% |
| Sep 30, 2021 | -356.99% |
| Jun 30, 2021 | -450.88% |
| Mar 31, 2021 | -322.00% |
| Dec 31, 2020 | -212.05% |
| Sep 30, 2020 | -238.81% |
| Jun 30, 2020 | -284.21% |
| Mar 31, 2020 | -160.24% |
| Dec 31, 2019 | -280.16% |
| Sep 30, 2019 | -153.40% |
| Jun 30, 2019 | -117.74% |